Literature DB >> 34396390

Response to Klar and Adams.

Gwen M H E Dackus1,2, Katarzyna Jóźwiak3,4, Michael Hauptmann3,4, Sabine C Linn1,2,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34396390      PMCID： PMC8755494          DOI： 10.1093/jnci/djab153

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   11.816


× No keyword cloud information.
  5 in total

Review 1.  Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis.

Authors:  A Zavos; A Valachis
Journal:  Acta Oncol       Date:  2016-04-22       Impact factor: 4.089

2.  The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Authors:  Jacquie Chirgwin; Zhuoxin Sun; Ian Smith; Karen N Price; Beat Thürlimann; Bent Ejlertsen; Hervé Bonnefoi; Meredith M Regan; Aron Goldhirsch; Alan S Coates
Journal:  Breast Cancer Res Treat       Date:  2011-09-04       Impact factor: 4.872

3.  Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Authors:  Joanne L Blum; Patrick J Flynn; Greg Yothers; Lina Asmar; Charles E Geyer; Samuel A Jacobs; Nicholas J Robert; Judith O Hopkins; Joyce A O'Shaughnessy; Chau T Dang; Henry Leonidas Gómez; Louis Fehrenbacher; Svetislava J Vukelja; Alan P Lyss; Devchand Paul; Adam M Brufsky; Jong-Hyeon Jeong; Linda H Colangelo; Sandra M Swain; Eleftherios P Mamounas; Stephen E Jones; Norman Wolmark
Journal:  J Clin Oncol       Date:  2017-04-11       Impact factor: 44.544

4.  NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Authors:  William J Gradishar; Meena S Moran; Jame Abraham; Rebecca Aft; Doreen Agnese; Kimberly H Allison; Sarah L Blair; Harold J Burstein; Chau Dang; Anthony D Elias; Sharon H Giordano; Matthew P Goetz; Lori J Goldstein; Sara A Hurvitz; Steven J Isakoff; Rachel C Jankowitz; Sara H Javid; Jairam Krishnamurthy; Marilyn Leitch; Janice Lyons; Jennifer Matro; Ingrid A Mayer; Joanne Mortimer; Ruth M O'Regan; Sameer A Patel; Lori J Pierce; Hope S Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Erica M Stringer-Reasor; Melinda L Telli; John H Ward; Kari B Wisinski; Jessica S Young; Jennifer L Burns; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2021-05-01       Impact factor: 11.908

5.  RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.

Authors:  Natalie Klar; Sylvia Adams
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.